Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 1;112(4):418-422.
doi: 10.1093/jnci/djz194.

Considerations When Using Breast Cancer Risk Models for Women With Negative BRCA1/BRCA2 Mutation Results

Affiliations
Free PMC article

Considerations When Using Breast Cancer Risk Models for Women With Negative BRCA1/BRCA2 Mutation Results

Robert J MacInnis et al. J Natl Cancer Inst. .
Free PMC article

Abstract

The performance of breast cancer risk models for women with a family history but negative BRCA1 and/or BRCA2 mutation test results is uncertain. We calculated the cumulative 10-year invasive breast cancer risk at cohort entry for 14 657 unaffected women (96.1% had an affected relative) not known to carry BRCA1 or BRCA2 mutations at baseline using three pedigree-based models (Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm, BRCAPRO, and International Breast Cancer Intervention Study). During follow-up, 482 women were diagnosed with invasive breast cancer. Mutation testing was conducted independent of incident cancers. All models underpredicted risk by 26.3%-56.7% for women who tested negative but whose relatives had not been tested (n = 1363; 63 breast cancers). Although replication studies with larger sample sizes are needed, until these models are recalibrated for women who test negative and have no relatives tested, caution should be used when considering changing the breast cancer risk management intensity of such women based on risk estimates from these models.

Similar articles

  • Genetic Tests for Breast and Ovarian Cancer [Internet].
    Juvet LK, Natvig Norderhaug I. Juvet LK, et al. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2008 Feb. Report from Norwegian Knowledge Centre for the Health Services (NOKC) No. 05-2008. Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH). 2008. PMID: 29319983 Free Books & Documents. Review.
  • 10-year performance of four models of breast cancer risk: a validation study.
    Terry MB, Liao Y, Whittemore AS, Leoce N, Buchsbaum R, Zeinomar N, Dite GS, Chung WK, Knight JA, Southey MC, Milne RL, Goldgar D, Giles GG, McLachlan SA, Friedlander ML, Weideman PC, Glendon G, Nesci S, Andrulis IL, John EM, Phillips KA, Daly MB, Buys SS, Hopper JL, MacInnis RJ. Terry MB, et al. Lancet Oncol. 2019 Apr;20(4):504-517. doi: 10.1016/S1470-2045(18)30902-1. Epub 2019 Feb 21. Lancet Oncol. 2019. PMID: 30799262
  • Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
    Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC; BRCA1 and BRCA2 Cohort Consortium, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H. Kuchenbaecker KB, et al. JAMA. 2017 Jun 20;317(23):2402-2416. doi: 10.1001/jama.2017.7112. JAMA. 2017. PMID: 28632866
  • Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.
    Metcalfe KA, Finch A, Poll A, Horsman D, Kim-Sing C, Scott J, Royer R, Sun P, Narod SA. Metcalfe KA, et al. Br J Cancer. 2009 Jan 27;100(2):421-5. doi: 10.1038/sj.bjc.6604830. Epub 2008 Dec 16. Br J Cancer. 2009. PMID: 19088722 Free PMC article.
  • Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    Eleje GU, Eke AC, Ezebialu IU, Ikechebelu JI, Ugwu EO, Okonkwo OO. Eleje GU, et al. Cochrane Database Syst Rev. 2018 Aug 24;8(8):CD012464. doi: 10.1002/14651858.CD012464.pub2. Cochrane Database Syst Rev. 2018. PMID: 30141832 Free PMC article. Review.
See all similar articles

LinkOut - more resources

Feedback